Background: Glycogen Synthase Kinase-3 (GSK3) activity is repressed following insulin treatment of cells. Pharmacological inhibition of GSK3 mimics the effect of insulin on Phosphoenolpyruvate Carboxykinase (PEPCK), Glucose-6 Phosphatase (G6Pase) and IGF binding protein-1 (IGFBP1) gene expression. CAAT/enhancer binding protein alpha (C/EBP ) regulates these gene promoters in liver and is phosphorylated on two residues (T222/T226) by GSK3, although the functional outcome of the phosphorylation has not been established. We aimed to establish whether CEBP is a link between GSK3 and these gene promoters.
Background
Glycogen synthase kinase-3 (GSK3), an insulin-inhibited protein kinase, has been linked to the control of many cellular processes [1] . It was originally identified as the protein kinase that phosphorylated and inactivated glycogen synthase in rabbit muscle [2] . Two highly related forms of GSK3 (GSK3 and GSK3 ) are expressed from distinct genes [3, 4] . They share greater than 95% identity in their kinase domains and appear to be ubiquitously expressed in mammals [3, 4] . In resting cells GSK3 activity is high and inhibition of the kinase is achieved by at least two mechanisms, firstly through phosphorylation of an N-terminal serine residue (Ser-21 in GSK3 , Ser-9 in GSK3 ) [5, 6] , and secondly through protein protein interaction [7] . Insulin promotes the phosphorylation of Ser-9/21 of GSK3 by activation of protein kinase B (PKB, also known as c-AKT) [8] , while canonical wnt signalling inhibits GSK3 independently of this N-terminal phosphorylation [9] .
In liver, inhibition of GSK3 reduces expression of the Phosphoenolpyruvate Carboxykinase (PEPCK) and Glucose-6 Phosphatase (G6Pase) genes, two rate limiting enzymes in hepatic glucose production [10] , as well as the IGF binding protein-1 (IGFBP1) gene [11] . These gene promoters share a related DNA sequence termed the thymine-rich insulin response element (TIRE) that plays an important role in their response to insulin [12] [13] [14] . Expression of these genes as well as GSK3 activity is abnormally high in insulin resistant states such as Type 2 diabetes mellitus (T2DM) [15] [16] [17] [18] [19] . Meanwhile overexpression of GSK3 antagonises insulin regulation of IGFBP1 [11] . Therefore inhibition of GSK3 is proposed as a potential target for the treatment of T2DM [1, 20, 21] . Indeed selective GSK3 inhibitors significantly reduce hepatic glucose output and blood glucose levels in several animal models of obesity and diabetes [22] [23] [24] [25] . However, GSK3 is reported to have over 30 substrates, and mutation of one of these, APC, is linked to the development of colonic cancer [20, 21, 26] . In addition, genetic deletion of one of the isoforms (GSK3 ) leads to liver cell death, possibly due to increased sensitivity to TNF [27] . Hence great care and consideration is being given to the development of GSK3 inhibitors for use in humans. With this in mind we have initiated a search for molecules that link GSK3 to the gluconeogenic gene promoters and in particular the TIRE, since inhibition of GSK3 is sufficient to repress the isolated DNA element [11] . Identification of the GSK3 substrate(s) that regulates IGFBP1, G6Pase and PEPCK gene expression, may permit manipulation of this specific interaction without affecting other GSK3 targets, thereby reducing potential side effects. GSK3 is an unusual kinase in that most substrates must be phosphorylated (primed) on a Ser/Thr four or five residues C-terminal to the GSK3 target residue (see [1] for review). Priming of the substrate is performed by a distinct protein kinase, therefore inhibition of the priming kinase indirectly inhibits GSK3 regulation of the substrate, but only those substrates primed by that particular priming kinase. Priming kinases are potential targets for more specific interference with GSK3 function.
The basic leucine zipper transcription factor, CAATenhancer binding protein alpha (C/EBP ) is a potential link between GSK3 and the gluconeogenic genes based on the following information in the literature; 1) C/EBP is phosphorylated on two residues (T222 and T226, numbers refer to rodent sequence) by GSK3, although the functional effect of phosphorylation is not yet clear [28] , 2) C/EBP is a key molecule in the regulation of the PEPCK and G6Pase gene promoters by cAMP [29] [30] [31] [32] [33] and T3 [34] , 3) C/EBP is regulated by wnt [35] and insulin [36, 37] in brown adipocytes, and the insulin regulation involves PKB (a regulator of GSK3) [37] , 4) PEPCK and G6Pase expression, as well as glucose and glycogen metabolism is abnormal in animals lacking C/EBP [38] [39] [40] and 5) binding of a TIRE-interacting protein is blocked using an oligonucleotide representing a known C/EBP binding sequence [41] .
Therefore, we attempted to determine whether C/EBP could modulate the activity of the isolated TIRE, or the gene promoters of interest, in a GSK3 regulated manner. In addition, although T222/T226 of C/EBP were identified as targets for GSK3 it has not previously been established whether S230 was a target for a 'priming' kinase, so we have also investigated whether mutation of S230 influences C/EBP regulation.
Results and discussion

C/EBP regulates the TIRE independently of T222/226 phosphorylation
We have previously shown that insulin, or pharmacological inhibition of GSK3, reduced the expression of endogenous PEPCK, G6Pase and IGFBP1 genes and also the activity of the isolated thymine-rich insulin response element (TIRE) found in these gene promoters [10, 11] . In an attempt to further characterise the GSK3 regulation of PEPCK, G6Pase and IGFBP1 we assessed whether a target for GSK3, namely C/EBP , could regulate TIRE activity. In the hepatocyte C/EBP activity is linked to cAMP induction of genes, so insulin inhibition of C/EBP could explain repression of these genes by insulin. In this model, phosphorylation of C/EBP by GSK3 would have to induce C/EBP activity toward the TIRE. Interestingly, C/EBP overexpression had a repressive effect on TIRE activity in the rat hepatoma H4IIE cells ( Fig 1A) , and the repression was lost when the TIRE sequence was mutated at two residues to produce an insulin insensitive sequence (DM5 [42] ; Fig 1A) . Hence C/EBP regulated the TIRE in a sequence specific and insulin-like manner. However, mutation of the GSK3-regulated residues on C/EBP (T222/T226/S230) to alanines (C/EBP -AAA) did not alter the ability of C/EBP to repress TIRE activity ( Fig  1A) . One possibility is that the dephosphorylated form of C/EBP repressed the TIRE, and that the overexpressed C/ EBP was not substantially phosphorylated by GSK3. Consistent with this hypothesis, co-expression of an active form of GSK3 reduced the effect of wild-type C/EBP on the TIRE ( Fig 1B) . Unfortunately, increased GSK3 activity also blocked the repressive action of the C/EBP -AAA ( Fig  1B) clearly demonstrating that phosphorylation of T222/ T226/S230 was not required for the action of GSK3 on the isolated TIRE in H4IIE cells. This data questioned the functional importance of T222/T226 phosphorylation in the regulation of C/EBP activity.
C/EBP phosphorylation in intact cells
Figure 2
C/EBP phosphorylation in intact cells. AD293 cells were transiently transfected with Flag-C/EBP (10 g) prior to incubation with CHIR99021 as indicated (A). Cell lysates were then subjected to Western Blotting with the antibodies as labelled. A representative immunoblot (of 2 two separate experiments) is given. (B) AD293 cells were transfected with Flag-C/EBP (10 g) plus GSK3 -V5 (10 g) or pcDNA6 (10 g) prior to 24 h incubation with CHIR99021 (2 M), lysis and Western Blot analysis. A representative immunoblot (of three separate experiments) is given. (C) H4IIE cells were infected with adenovirus expressing Flag-C/EBP . After 16 h the infected cells were serum starved for 3 h prior to incubation with or without insulin (10 nM) or CHIR99021 (2 M) for the times indicated. Cell lysates were immunoblotted with the antibodies indicated and a representative experiment is provided. 
GSK3 phosphorylates C/EBP in intact cells
It was therefore important to establish whether T222 and T226 were actually phosphorylated by GSK3 in intact cells. Cells were transfected with wild-type and mutant C/ EBP and total and phosphorylated C/EBP visualised by Western Blotting. T222/226 phosphorylation, measured with this antibody, was clearly present in intact cells ( Fig  2) . Incubation with 1 or 2 M of the GSK3 inhibitor CHIR99021 [11, 43] for 6 or 24 h significantly reduced the phosphorylation of T222/226 of wild-type C/EBP ( Fig  2A) , confirming that GSK3 was a T222/226 kinase in these cells. At shorter incubations, 1 M CHIR99021 was sufficient to give maximal reduction in T222/226 phosphorylation, while 2 M had a greater effect at 24 h incubation. This is similar to the effect of these concentrations oncatenin activation in the H4IIE cells [11] . Meanwhile, coexpression of active GSK3 ( Fig 2B) only produced a marginal induction of phosphorylation (around 1.2 fold) suggesting that the expressed C/EBP was either almost fully phosphorylated at T222/226 or that it was not a particularly good substrate for GSK3. Mutation of T222/226 to alanines made the mutant C/EBP unresponsive to the phosphospecific antibody (see later). Interestingly, the dephosphorylation of C/EBP in H4IIE cells treated with CHIR99021 was rapid, but not complete ( Fig 2C) . However, there was no significant reduction in T222/226 phosphorylation following up to 2 h incubation with insulin ( Fig 2C and Fig 3) , even though insulin promoted phosphorylation of Ser9/Ser21 of GSK3 and GSK3 respectively. Insulin reduced GSK3 activity around 50% in the H4IIE cell line but this is clearly not sufficient to reduce T222/226 phosphorylation. Therefore it appears that insulin does not regulate T222/226 phosphorylation in these cells through inhibition of GSK3. However, the data suggested that some level of T222/226 phosphorylation by GSK3 occurs on the overexpressed protein ( Fig  2C) . 
C/EBP phosphorylation in vitro
C/EBP is a relatively poor substrate for GSK3 in vitro
We next characterised C/EBP phosphorylation by GSK3 in vitro (Fig 4) . Incubation of C/EBP with GSK3 for up to one hour resulted in a slow incorporation of less than 0.03 mol phosphate per mol of protein ( Fig 4A and 4B) . In comparison, p42MAP kinase phosphorylation of C/ EBP increased over 60 min peaking around 1.5 mol per mol ( Fig 4A and 4B) . Phosphorylation of C/EBP by p42MAP kinase did not occur at T222, T226 or S230 (see below) and is more likely to be on S21 [44] . Interestingly western blot analysis of C/EBP following incubation with GSK3 gave little indication of this slow increase in phosphorylation, and a very strong signal was obtained with the phosphospecific antibody even at low stoichiometry of phosphorylation ( Fig 4C) . These data demonstrated that C/EBP was a relatively poor substrate for GSK3 in vitro ,but that the phospho-T222/226 antibody was highly sensitive. It is difficult to directly compare phosphorylation of C/EBP with other substrates of GSK3 as most are poorly phosphorylated prior to priming. For example CRMP phosphorylation by GSK3 (under identical conditions to those used for C/EBP in Fig 4) incorporates around 0.2 mol/mol phosphate within 2 h of incubation [45] . However, this increases more than 5-fold if the substrate is first primed. Of course we can never rule out the possibility that an intrinsic factor improves the GSK3-C/EBP interaction in vivo ,either promoting prim-ing at an unidentified residue or allowing greater phosphorylation by GSK3.
GSK3 phosphorylation of T222/226 in cells does not require S230 phosphorylation
Many substrates of GSK3 are primed for kinase recognition by prior phosphorylation at a S/T residue four amino acids C-terminal to the target site [1] . S230 lies within this 'consensus' GSK3 targeting sequence ( Table 2) . Therefore S230 phosphorylation could prime for T226 phosphorylation by GSK3, permitting subsequent phosphorylation of T222 by GSK3. However, mutation of S230 to alanine had no effect on T222/226 phosphorylation in intact cells ( Fig 5) . This argued that S230 phosphorylation did not prime for T226 phosphorylation by GSK3 in resting cells, or that the wild-type C/EBP is not being efficiently phosphorylated at S230. Since the amino acid immediately following S230 is a proline ( Table 2) , we hypothesised that priming may only occur after induction of a prolinedirected kinase such as a member of the MAP kinase family. Therefore we attempted to induce S230 phosphorylation by incubation of cells with serum, which stimulates the classical MAP kinase and several other prolinedirected kinases such as cyclin-dependent kinases. However, T222/226 phosphorylation of wild-type or S230A C/ EBP was not altered in serum treated cells ( Fig 5B) , despite activation of the p90RSK downstream of the p42/ p44MAP kinase ( Fig 5B) . This demonstrated we could not alter S230 phosphorylation by incubating cells with or without serum. Interestingly, serum treatment induced phosphorylation of S21/9 of GSK3 / ( Fig 5B) , suggesting some inhibition of GSK3 occurs in the serum treated cells. This was not sufficient to reduce C/EBP phosphorylation but did partially reduce glycogen synthase phosphorylation (a known substrate of GSK3 ( [46] ; Fig 5B) . Similarly, treatment of the cells with CHIR99021 did not completely inhibit T222/226 phosphorylation (Fig 2 and  Fig 3) , despite a complete loss of glycogen synthase phosphorylation ( Fig 5B) . Therefore T222/226 must be rela- -GGA TCC GCC ACC ATG GAC TAG AAG GAC GAC GAT GAC AAG GAG TCG GCC GAC TTC  TAC GAG-3 tively resistant to dephosphorylation or a distinct T222/ 226 protein kinase must be present in these cells. Again, potential substrates for GSK3 have been reported that have their priming at a residue more distant from the GSK3 target site, and we cannot discount that possibility. However, our data strongly argues against priming through S230 phosphorylation.
Prephosphorylation of CEBP by p42 MAP kinase did not prime for subsequent phosphorylation by GSK3 in vitro ( Fig 6A) , confirming that S230 is not targeted by p42 MAP kinase. Similarly, incubation of cells with either a p42MAP kinase inhibitor (PD98059) or a p38MAP kinase inhibitor (SB203580) had no effect on phosphorylation of CEBP at T222/226 ( Fig 6B) .
C/EBP induced a consensus binding element while repressing the TIRE in H4IIE cells
In contrast to the repressive action on TIRE activity, overexpression of C/EBP in H4IIE cells induced the activity of a consensus C/EBP binding element (CBE) ( Fig 7A) . We were therefore able to investigate whether the GSK3 regulation of T222/T226 was dependent on the DNA sequence analysed. Mutation of T222/226/S230 to alanines (in any combination) made no difference to the induction of the CBE by C/EBP ( Fig 7A) . Similarly, inhibition of GSK3 using CHIR99021 or insulin had no effect on CBE activity (Fig 7A and 7B) . Therefore GSK3 phosphorylation of T222/226 does not regulate either induction of the CBE or repression of the TIRE in the H4IIE cells. Interestingly CBE activity was induced in the presence of the synthetic glucocorticoid dexamethasone to a similar level as that seen with C/EBP overexpression ( Fig 7B) .
C/EBP overexpression does not regulate endogenous TIRE-containing genes
In order to establish whether changes in C/EBP phosphorylation could alter expression of the insulin regulated genes IGFBP1 and G6Pase, we overexpressed C/EBP in H4IIE cells using an adenoviral vector to produce almost 100% transfection efficiency (Figs 8, 9, 10 ). We observed no effect of C/EBP expression on IGFBP1 (Fig 8) or G6Pase (Fig 9) gene expression, and no alteration in regulation of either gene by dexamethasone, insulin or CHIR99021. However, there was a significant repression of the co-expressed BP1-TIRE by C/EBP when compared with its effect on the insulin resistant TIRE (DM5) ( Fig  10) . This suggests that C/EBP overexpression represses the isolated element but has no effect on this element when it is in the context of the intact gene promoters. This is an example of the dangers of studying isolated promoter elements and extrapolating to intact gene promoters without examining endogenous regulation. Interestingly, a postnatal knockout of C/EBP resulted in reduced basal expression of PEPCK and G6Pase but did not alter regulation of these genes by cAMP [40] . Again, 
Regulation of endogenous IGFBP1 gene expression in H4IIE cells following C/EBP overexpression
C/EBP regulation of the CBE in preadipocytes is greater when T222/226 are mutated
C/EBP has an important role in adipocyte differentiation [37, 47, 48] , therefore we transfected 3T3-L1 preadipocytes with C/EBP and measured CBE activity ( Fig 11A) . In contrast to the H4IIE cells, mutation of T222/226 to alanines resulted in a significant increase in transactivation potential compared to wild-type C/EBP ( Fig 11A) . This suggested that phosphorylation of these residues was inhibiting C/EBP activity in these cells. Consistent with this hypothesis, inhibition of GSK3 using CHIR99021 or insulin induced wild-type C/EBP activity ( Fig 11A) . In addition, the C/EBP S230A mutant had similar transactivation potential to the AA mutant ( Fig 11A) , strongly suggesting that S230 was a priming site for T222/T226 phosphorylation in these cells. However we could find no evidence that phosphorylation of T222/226 was reduced in the S230A mutant ( Fig 11B) . Although there was a great deal of inter-experiment variation in the phosphorylation of T222/T226 in the WT and the S230A mutant there was not a significant difference between the two, and in 2 out of the three experiments the S230A mutant exhibited higher phosphorylation than the WT protein ( Fig 11B) . Therefore, changes in phosphorylation of these two sites cannot account for the difference in C/EBP activity when the S230 site is mutated to alanine. Ideally it would be beneficial to confirm these data on endogenous gene expression in the adipocyte cell line, however these cells do not transfect efficiently with the adenoviral constructs making it impossible to examine their effect on endogenous genes.
Conclusion
In summary, C/EBP is not the link between GSK3 and the hepatic TIRE-containing gene promoters. However, C/ EBP can regulate the TIRE, at least when overexpressed, and the residues T222/226 and S230 all influence C/EBP function in preadipocytes. Interestingly we demonstrate opposite effects of C/EBP overexpression on TIRE and CBE activity, and a tissue specific role for the T222/226 motif in this activity. Our data also provides further evidence of the differences in transcription factor activity when measured using isolated promoter elements as opposed to intact gene promoters. During the course of this study a regulation of C/EBP by GSK3 in adipocytes
Regulation of the isolated TIRE in H4IIE cells following C/ EBP overexpression Regulation of endogenous G6Pase gene expression in H4IIE cells following C/EBP overexpression Figure 9 Regulation of endogenous G6Pase gene expression in H4IIE cells following C/EBP overexpression. RNA produced as in Fig. 8 was analysed for G6Pase expression by RPA. Expression was calculated relative to cyclophilin mRNA levels. Data are presented as the average ± SEM of three experiments, with a representative autoradiograph shown in the upper panels. was reported [49] . Therefore it will be of interest to confirm whether this C/EBP isoform is the link between GSK3 inhibition and TIRE regulation in hepatocytes.
Methods
Material
Radioisotopes [ - 32 
Construction of plasmid DNA, luciferase reporter, and mutagenesis
The full length C/EBP cDNA was amplified by PCR from a rat L6 cDNA library and BamHI/Kosac/Flag and EcoRl sequences introduced at the 5' and 3' end respectively as indicated in Table 1 . The PCR product was subcloned into TOPO one shot (Invitrogen), verified by DNA sequencing, and subcloned into pcDNA6, GST-pGEX-6, and pshuttle-CMV vectors for the purpose of expression in mammalian cells, production of recombinant GST-tagged protein in Escherichia coli BL21 cells, and construction of recombinant adenovirus (AdEasy XL Adenoviral Vector System, Stratagene), respectively. Flag-C/EBP point mutants, S230A, T222A/T226A (AA), and T222A/T226A/S230A (AAA) were generated using the QuickChange mutagenesis kit (Stratagene) with the oligo sequences shown in Table 1 . The AAA mutant was generated by introducing the S230A point mutation into the AA mutant. A luciferase reporter construct containing a C/EBP consensus binding sequence (CBE-Luc) 5' of a thymidine kinase promoter was constructed using the oligos shown in Table 1 . Both sense and antisense oligos were annealed prior to restriction digest with Kpnl and Bgl II. The product was subcloned into the BP1 luciferase reporter linearised with Kpnl and BamHI to remove the TIRE (the luciferase con- 
Transient transfection
AD293 cells were transiently transfected with 10 g of pcDNA6, Flag-C/EBP , AA, AAA, or S230A mutants by the calcium phosphate method. DNA precipitant was added to cells for 4 h, prior to addition of inhibitors and hormones at the concentrations and for the times indicated in figure legends.
H4IIE cells were transfected as described previously [50] . Briefly, 10 g of BP1-TIRE-Luc, the insulin insensitive point mutant of the TIRE (DM5-Luc), C/EBP-Luc, or pGL3-Luc (control), along with 1 g of pcDNA6, wild type or mutant Flag-C/EBP constructs were precipitated and incubated with H4IIE cells in suspension. Cells were plated onto 10 cm dishes, allowed to attach for 4 h, prior to DMSO shock and incubation with hormones/inhibitors for 20 h as indicated in figure legends. Cells were lysed in 200 l lysis buffer (Promega, UK), the cell debris removed by centrifugation at 13,000 × g for 10 min at 4°C, and the supernatant stored at -70°C. Luciferase assays were performed using the firefly luciferase assay system (Promega, UK), according to manufacturer's instructions, with luciferase activity being corrected for the protein concentration in the cell lysate.
3T3-L1 preadipocytes were transfected using Fugene 6 Transfection Reagent (Roche) following manufacture's protocol. C/EBP-Luc (2 g) along with 200 ng of pcDNA6, wild type or mutant Flag-C/EBP constructs was complexed with Fugene 6 transfection reagent prediluted in Serum Free DMEM at the ratio of 1:3 ( g DNA : l Fugene 6) for 20 min at RT before addition to cells. After 4 h at 37°C an equal amount of DMEM containing 20% foetal calf serum was added. 48 h post-transfection, cells were washed with serum free DMEM and incubated for a further 24 h in serum free media with or without hormones or inhibitors as described in figure legends. Cells were lysed in 100 l lysis buffer and luciferase activity determined as above.
We estimate that the level of over expression of C/EBP is roughly 4 fold in the adipocytes, around 6-fold in the liver cells by transient transfection and nearly 10 fold in adenovirally infected H4IIE experiments
In vitro phosphorylation of C/EBP
Purified recombinant C/EBP (6 pmol) was incubated at 30°C with His 6 -GSK3 (2 U/ml) or p42 MAPK (10 U/ml), 10 mM magnesium acetate, 0.1 mM [ -32 P]ATP (450,000 cpm/nmol) in buffer containing 50 mM Tris-HCl, pH 7.5, 0.03% (v/v) Brij 35, and 0.1% (v/v) 2-mercaptoethanol, for times indicated in the figure legends. Reactions were stopped by the addition of LDS containing sample buffer (Novex), heated at 70°C for 10 min and subjected to SDS-PAGE. The gel was dried on the 3 M Filterpaper, and radioactivity incorporated into recombinant C/EBP visualized by autoradiography and quantified by phosphorimager (Fuji). A standard curve of radiolabelled ATP was used to assess nmoles of phosphate incorporated into the C/EBP substrate. p42 MAP kinase and GSK3 activities were calculated by in vitro phosphorylation of myelin basic protein and P-GS peptide, respectively.
Preparation of cell extract for SDS PAGE and Immunoblotting
Cells were washed with ice cold PBS twice and scraped into ice-cold lysis buffer (25 mM Tris/HCl, pH 7.4, 50 mM NaF, 100 mM NaCl, 1 mM sodium vanadate, 5 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 10 mM sodium pyrophosphate, 1 mM benzamidine, 0.1 mM PMSF, 0.27 M sucrose, 2 M microcystin and 0.1% (v/v) 2-mercaptoethanol). Cell debris was removed by centrifugation at 13,000 × g for 10 min at 4°C. Preparation of nuclear protein extracts was performed using a Nuclear Extraction Kit (Panomics), as per the manufacture's instructions. The protein concentration was determined by Bradford assay (Sigma), using BSA as standard as per the manufacture's instructions. Protein from cell lines (10-20 g from H4IIE, 50 g from AD293 or 3T3 preadipocytes) was separated on Novex SDS 4-12% polyacrylamide gels. Following transfer to nitrocellulose, blots were blocked with 5% (w/v) non-fat milk in TBST (Tris-buffered saline containing 0.1% (v/v) Tween 20) for 1 h, and incubated with primary antibodies at 4°C overnight prior to incubation for 1 h at RT with the secondary antibody and development using ECL kit (Amersham Biosciences, Inc.).
Adenoviral Infection, RNA extraction and RNAse protection assay
For RNA studies, H4IIE cells were infected with recombinant adenovirus expressing Flag-C/EBP (Ad-C/EBP ) or -Galactosidase (Ad--gal) for 4 h at MOI = 50. 24 h later, infected cells were split into 10 cm dishes and serum starved overnight prior to treatment with hormone/inhibitor for 3 h at the concentrations indicated in the figure legends. Total cellular RNA was isolated using TRI Reagent (Sigma) following the manufacturer's instructions. An RNase Protection Assay (RPA) was performed to determine the relative amounts of IGFBP-1, G6Pase, and cyclophilin mRNA as described previously [50] . Band intensity was quantified on a phosphorimager (Fuji), data calculated as a ratio of IGFBP-1 to cyclophilin mRNA. For phosphorylation studies, H4IIE cells were infected with recombinant adenovirus expressing Flag-C/EBP (Ad-C/ EBP ) at MOI = 100. 16 h later, infected cells were serum starved for 3 h prior to treatment with hormone/inhibitor for the times and at the concentrations indicated in the figure legends.
Statistics
The comparison of one variable between two groups was determined by unpaired Student's t-test with the aid of PRISM 3.0 (Graphpad Software, USA) and/or Microsoft Excel. The values were expressed as mean ± S.E.M.
